NNVC - NanoViricides, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
7.61
-0.09 (-1.17%)
As of 1:41PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close7.70
Open7.70
Bid7.54 x 800
Ask7.60 x 900
Day's Range7.36 - 7.75
52 Week Range1.27 - 19.20
Volume211,993
Avg. Volume1,265,819
Market Cap69.192M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-2.12
Earnings DateFeb 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    NanoViricides Announces Completion of $10.2 Million Registered Direct Offering - Funds to Accelerate COVID-19 Drug Program and HerpeCide™ Program

    SHELTON, CT / ACCESSWIRE / May 26, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that it has raised $10.22 Million in gross proceeds from the sale of 1.4 million shares of common stock, and no warrants, at a price of $7.30 per share, in a previously announced registered direct offering (the "Offering"). The co-Placement Agents were paid a total cash fee of 8% of the gross proceeds, plus $75,000 for reimbursement of legal fees. The net proceeds to the Company were approximately $9.327 Million, after deducting placement agent fees and other costs.

  • ACCESSWIRE

    NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering

    SHELTON, CT / ACCESSWIRE / May 21, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has entered into a securities purchase agreement with several institutional investors for the issuance and sale of 1,400,000 shares of its common stock at a price of $7.30 per share, for aggregate gross proceeds of approximately $10.22 million, in a registered direct offering. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc., are acting as co-placement agents for the offering.

  • ACCESSWIRE

    Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus

    SHELTON, CT / ACCESSWIRE / May 20, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. NanoViricides is developing an animal model for coronavirus infection using hCoV-NL63 as a surrogate for SARS-CoV-2, the virus that causes COVID-19 disease.

  • ACCESSWIRE

    Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc.

    SHELTON, CT / ACCESSWIRE / May 18, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that Honorable Mr. Todd Rokita, J.D., former member of the U.S. House of Representatives from Indiana, has joined the Company's Board of Directors, effective May 15, 2020, as an independent director. Most recently, Mr. Rokita has been nominated by President Trump to the Board of Directors of the National Railroad Passenger Corporation (aka Amtrak), pending U.S. Senate Confirmation.

  • Company News for May 13, 2020
    Zacks

    Company News for May 13, 2020

    Companies In The News Are: GMDA, NNVC, CHAP, YRCW

  • NanoViricides: New Covid-19 Drug Candidates Could Boost Performance
    GuruFocus.com

    NanoViricides: New Covid-19 Drug Candidates Could Boost Performance

    The research-focused biopharma player has made progress in developing and testing Continue reading...

  • ACCESSWIRE

    NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses

    SHELTON, CT / ACCESSWIRE / May 12, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that it has developed drug candidates that have demonstrated very high anti-viral effectiveness in cell culture studies against multiple coronaviruses. Two of the tested nanoviricides drug candidates were highly effective in cell culture assays against multiple coronaviruses that infect humans.

  • ACCESSWIRE

    NanoViricides Signs Confidential Disclosure Agreement with International Pharmaceutical Company to Explore Collaborating on its COVID-19 Program

    SHELTON, CT / ACCESSWIRE / May 4, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that it has signed a Confidential Disclosure Agreement ("CDA") with a leading pharmaceutical company in the Asian region to explore collaborating on the Company's COVID-19 program. NanoViricides previously disclosed that it has already identified certain drug candidates that are active against multiple coronaviruses in cell culture studies. The Company intends to perform testing against SARS-CoV-2 (the virus that causes COVID-19 disease) and is in advanced discussions with at least two sites that have such capability.

  • ACCESSWIRE

    NanoViricides Presentation on COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 is Now Available

    SHELTON, CT / ACCESSWIRE / April 29, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that the Company's presentation with an update of its drug development programs for the treatment of Shingles and for COVID-19 made at the Planet MicroCap Showcase 2020 on April 22nd is now available for viewing. Anil R. Diwan, PhD, President and Executive Chairman of the Company, presented this Corporate Update. The Company has drug candidates that were highly successful in cell culture studies against multiple coronaviruses.

  • ACCESSWIRE

    NanoViricides to Present COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 on April 22nd

    SHELTON, CN / ACCESSWIRE / April 21, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it will provide an update of its drug development programs for the treatment of Shingles and for COVID-19 when it presents an overview of the Company at the Planet MicroCap Showcase 2020 tomorrow, Wednesday, April 22 at 6:40 PM EST. Anil R. Diwan, PhD, President and Executive Chairman of the Company, will be presenting and answering questions from investors. One-on-one meetings will be scheduled and conducted via private, secure video conferencing through the conference event platform.

  • ACCESSWIRE

    NanoViricides’ President Dr. Anil Diwan was Interviewed by Proactive Investors About the Company’s Antiviral Drug Development Against SARS-CoV-2 to Treat COVID-19

    SHELTON, CT / ACCESSWIRE / April 13, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), states that its President, Dr. Anil R. Diwan was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading, multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London. The interview took place remotely, with Dr. Diwan and key staff members at the Company's Shelton, CT headquarters, on March 27, 2020. A video transcript of the interview published by Proactive Investors is now available at https://youtu.be/CLfTNbHcMzU and on the Company's website at www.nanoviricides.com.

  • Does NanoViricides, Inc. (NYSEMKT:NNVC) Have A High Beta?
    Simply Wall St.

    Does NanoViricides, Inc. (NYSEMKT:NNVC) Have A High Beta?

    Anyone researching NanoViricides, Inc. (NYSEMKT:NNVC) might want to consider the historical volatility of the share...

  • NanoViricides: The Visit From Senator Blumenthal Is a Positive Development
    GuruFocus.com

    NanoViricides: The Visit From Senator Blumenthal Is a Positive Development

    The company's Covid-19 drug puts it in contention for funding under the CARES Act Continue reading...

  • ACCESSWIRE

    U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus (COVID-19) Drug Development Efforts

    SHELTON, CT / ACCESSWIRE / April 6, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral drugs based on a novel, patented, nanomedicines platform, reports that U.S. Senator Richard Blumenthal visited the Company's facility in Shelton, Connecticut, on Tuesday, March 31, 2020. The Honorable Senator Blumenthal visited the Company to receive an update regarding the coronavirus (COVID-19) drug development program and to tour the cGMP-capable manufacturing facility.

  • NanoViricides, Inc. Progress on COVID-19 Drug Encouraging
    Newsfile

    NanoViricides, Inc. Progress on COVID-19 Drug Encouraging

    The Company's Update on its Development of COVID-19 Drug Candidate is Promising Vancouver, British Columbia--(Newsfile Corp. - March 31, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") is a nano-biopharmaceutical Company at the development stage, with proprietary and patented drug development work focused on viral diseases. The Company's research involves the use of a unique nanomedicine technology called nanoviricides -- agents designed to "fool" a virus into attaching to an antiviral nanomachine, in ...

  • ACCESSWIRE

    Coronavirus Drug Development Update from NanoViricides, Inc.

    SHELTON, CT / ACCESSWIRE / March 16, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. The Company has completed the synthesis of a number of nanoviricide drug candidates for testing in just a few weeks after identification of virus-binding ligands. This was possible because the Company is boot-strapping its efforts on the basis of its inventory of novel custom chemicals in hand.

  • The Coronavirus Pandemic Has Revealed Some Micro-Cap Opportunities
    GuruFocus.com

    The Coronavirus Pandemic Has Revealed Some Micro-Cap Opportunities

    With the Dow Jones and the S&P; 500 plummeting as a result of the coronavirus pandemic, a number of interesting micro-cap stocks have emerged as interesting bets Continue reading...

  • Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio?
    InvestorPlace

    Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio?

    In an increasingly sickly looking market, Inovio Pharmaceuticals (NASDAQ:INO) has been resurrected from a dead-like experience with investors. The question is, can it last? Let's take a look at what's pumping life into shares and whether INO stock is worth buying in today's market.Source: Ascannio / Shutterstock.com It's not the cure for cancer. But on Wall Street and where the coronavirus from China is spreading a bearish pandemic among risk-assets, shares of Inovio are acting like the cure-all in the eyes of many investors. The stock rocketed higher by nearly 230% on the week on staggering record-breaking volume of roughly 587 million shares.But there's more to the rally in Inovio as well.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe obvious bullish interest has allowed Inovio to close in on a 13-year high. Shares have also moved into the double digits above $14 a share as of Friday's close and firmly into small-cap territory with a market valuation of $1.43 billion. Furthermore and in safer venues than those around the workplace cooler, on the Yahoo Finance message boards, INO stock has enjoyed a healthy surge in conversations totaling more than 21,000.Yep, investors are suddenly and very definitely interested in Inovio Pharmaceuticals.Not that the stock is alone in its rapid validation among today's investors. There's Enzo Biochem (NYSE:ENZ), Nanoviricides (NYSEAMERICAN:NNVC) and Vir Biotechnology (NASDAQ:VIR), a more recognizable larger-cap stock like Gilead Sciences (NASDAQ:GILD). There's also a host of other companies which have caught Wall Street's attention in recent weeks as a well-contained COVID-19 health problem has become a global health and financial crisis. * 10 Best Stocks to Buy and Hold Forever The driver (of course) behind each of these companies' strong rallies has been an arms race of sorts to help remedy or solve the coronavirus in one way or another. But right now, Inovio does stand apart from many of the other biotechs tackling this problem.While INO stock is still mired in red ink, Inovio is the only company with an existing phase 2 vaccine used for the MERS or Middle East Respiratory Syndrome coronavirus. It's a big advantage. Also, this past week, Inovio announced it's accelerating the timeline for development of its DNA-based vaccine to this combat this new strain of coronavirus. Management expects human trials for INO-4800 to commence in April. But is all of this priced in already? INO Stock Price Monthly Chart Source: Charts by TradingViewAside from the aforementioned street-grabbing stats, INO stock has made other strong inroads as well. Most importantly, last week's rally burst shares out of six-year long downtrend as shown on the provided monthly chart. But don't think for a second it's clear sailing from here for today's buyers of Inovio Pharmaceuticals.The strong buying in Inovio now has the stock challenging the 50% retracement level from its 2004 relative high. Shares have also pierced, but fallen back below its MERS-related high of $15.80 set in 2014. Also, Inovio is in an overbought position as evidenced by its price extension above the upper Bollinger Band and the stock's monthly stochastics.Ultimately, I'm not overly enthusiastic on Inovio's longer-term prospects. I'd also stress that given the company's weak financial position and shares' rise to price levels associated with its last run-in with Wall Street's sell-side during the MERS outbreak, the stock is highly speculative. But for investors that dare to see things differently, I'd definitely recommend using the options market and a limited-risk strategy for positioning.The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Ways to Diversify Your Portfolio at This Time of Crisis * 3 Cannabis Stocks That Are Ready to Run * 5 High-Yield Dividend Stocks With Great Buyback Programs The post Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio? appeared first on InvestorPlace.

  • NanoViricides, Inc. Reports Discovery of Broad-Spectrum Virus-Binding Ligands; Expected to Counter COVID-19
    Newsfile

    NanoViricides, Inc. Reports Discovery of Broad-Spectrum Virus-Binding Ligands; Expected to Counter COVID-19

    The Company has been working on a drug candidate to address the COVID-19 and has made significant progress in this regard New York, New York--(Newsfile Corp. - March 5, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") is a nano-biopharmaceutical Company at the development stage, with proprietary and patented drug development work focused on viral diseases. The Company has recently been in the news for being one of the few biotechnology companies that ...

  • Benzinga

    18 Medical Stocks To Watch Amid The Coronavirus Outbreak

    Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Mon., Feb. 24, 2020: NNVC, WFC, SPCE, LL, CETX

    Benzinga Pro's Stocks To Watch For Monday NanoViricides (NNVC)  - Shares were up 30% ahead of the open as a continued increase in the number of coronavirus cases is the main headline impacting Wall Street ...

  • ACCESSWIRE

    NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2019 - Has Sufficient Cash, HerpeCide(TM) Drug Candidate IND Application Development in Progress

    SHELTON, CT / ACCESSWIRE / February 24, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its second quarter of financial year 2020 in a timely manner with the Securities and Exchange Commission. The Company reported that it had approximately $1.0 Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of approximately $1.4M excluding a recent mortgage (described below), as of December 31, 2019, the end of the reporting period. The Company's expenditures were in line with budget estimates.

  • The Wuhan Virus and Research-Focused Biotech Companies
    GuruFocus.com

    The Wuhan Virus and Research-Focused Biotech Companies

    With the spread of the new coronavirus from Wuhan, investors should consider investing in smaller biotech and pharma players Continue reading...

  • ACCESSWIRE

    Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc.

    SHELTON, CT / ACCESSWIRE / February 12, 2020 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, reports that Dr. Makarand "Mak" Jawadekar, a veteran Pharma industry expert professional, has been duly appointed as an Independent Director to its Board of Directors. Dr. Mak Jawadekar has been serving as a strategic advisor to pharmaceutical and biotechnology companies through his independent consultancy since 2010.

  • ACCESSWIRE

    Nanoviricides President Dr. Diwan Was Interviewed by The Varney Show on Fox Business News

    SHELTON, CT / ACCESSWIRE / February 10, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that Dr. Anil Diwan, the Company's President and Executive Chairman of the Board, was interviewed on the Stuart Varney show on Fox Business News (FBN), on January 28, 2020. The Company has licensed a copy of the video excerpt from FBN and it is available on the Company's website (www.nanoviricides.com), home page, under the heading "Dr. Anil Diwan on Fox Business - 01/28/2020".